Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT04435457 |
Other study ID # |
STU-2020-0359 |
Secondary ID |
|
Status |
Terminated |
Phase |
|
First received |
|
Last updated |
|
Start date |
September 1, 2020 |
Est. completion date |
May 20, 2023 |
Study information
Verified date |
May 2023 |
Source |
University of Texas Southwestern Medical Center |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
At the end of December of 2019, a series of patients in Wuhan, China were struck with a
mysterious respiratory infection. These isolated events have rapidly grown into a deadly,
global pandemic. This pandemic is caused by the Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2), which results in the Coronavirus Disease 2019 (COVID-19). For individuals
infected with COVID-19, approximately 30% of the hospitalized cases are associated with
cardiovascular complications. Data are emerging that individuals with pre-exiting conditions
(like hypertension, diabetes, cancer, or medical issues related to the immune system) are
most susceptible to complications related to COVID-19. Furthermore, individuals of certain
racial and ethnic backgrounds (e.g. African American and Hispanic) are at a higher risk of
death from COVID-19. Despite these emerging observations, it remains unclear who will develop
the cardiovascular complications (acute myocardial injury with evidence of a myocarditis-like
picture and cardiogenic shock) and what the long term sequelae of this disease will be for
survivors of this infection after hospitalization. Thus, the goals of this project are to
better understand the epidemiology of cardiac injury in acutely ill COVID-19 patients through
deep cardiac phenotyping and identify the molecular profile of individuals most susceptible
to cardiac injury from COVID-19.
Description:
This will be a cross-sectional cohort study of participants who will undergo a detailed
cardiovascular imaging evaluation and blood draw once they have recuperated from a prior
index-hospitalization at Clements University Hospital or Parkland Memorial Hospital in
Dallas, Texas, USA for COVID-19 and are no longer contagious (~4-6 weeks post
hospitalization). Due to the uncertainty with which the extent of cardiac injury represents
phenotypic cardiac manifestations in COVID-19, the investigators plan to enroll individuals
according to their highest, in-hospital, (high sensitivity - cardiac troponin T) hs-cTnT. The
following proposed stratification scheme will afford testing a spectrum hs-cTnT levels.
Table: Enrollment strata by hs-cTnT (N=70)
hs-cTnT [ng/L] < 50 50-100 101-500 > 500
Enrollment N=20 N=20 N=20 N=10
The investigators propose the following exploratory protocol for deep phenotyping to
characterize surviving patients with COVID-19 and elevated hs-cTnT during hospitalization.
All participants will undergo a protocolized multiparametric cardiac magnetic resonance
imaging (CMR) assessment with an electrocardiography-gated breath hold protocol under the
oversight of study personnel and read by a reader blinded to hs-cTnT data from the COVID-19
index hospitalization. Conventional 1H CMR evaluations will include T2 maps, native and
post-contrast T1 maps, as well as extracellular volume index calculation and late gadolinium
for inflammatory injury. Standardized adenosine hyperemic stress perfusion CMR will be
performed for quantitative myocardial blood flow analysis. In addition to conventional 1H CMR
a subset of 5 patients from the highest and lowest troponin groups, age- and BMI-matched,
will undergo hyperpolarized 13C metabolic CMR with infusion of [1-13C] pyruvate under fasting
conditions to assess inflammation and post carbohydrate load to assess a decrease in
myocardial mitochondrial oxidative metabolism.
Biospecimens will be collected by study personnel at the time of CMR or preliminary study
site visit. A fasting venous blood sample (50 cc) will be collected, maintained on ice and
transported to the Mammen Laboratory, which is located on the campus of UT Southwestern. Both
serum and plasma will be isolated and aliquoted for storage and immediately frozen and stored
until use and will not undergo any freeze-thaw cycles. RNA and protein will be extracted from
the samples for biomarker and autoantibody (AAb) assays. The presence of cardiac-specific
AAbs has been shown to be involved in both the manifestation and development of cardiac
disease manifestation and predicting disease development. Utilizing a customized ELISA-based
detection assay, ~20 circulating cardiac-specific AAbs that have been reported to be
associated with heart failure will be assessed and quantified during the early (1-2 months
post-hospitalization) phases of the patient post COVID-19 hospitalization course.
Leukocytes will be isolated from the biospecimens samples and genomic DNA will be extracted
from the cells to perform Next Generation Whole Exome Sequencing (WES). These studies will be
undertaken in the Next-Generation Sequencing Core on campus. Capitalizing on a
well-established research collaboration between the Mammen Laboratory and the McDermott
bioinformatics group, the WES data will be analyzed for genetic mutations associated with
cardiomyopathy as well as autoimmunity.
If funds are available, both the imaging and molecular assessments will be duplicated in
individuals with paired data after an additional 10-12 months from hospitalization.